Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease in Phase 1, Phase 1b/2a and Phase 1b Studies
January 06, 2023 08:10 ET
|
Celularity, Inc.
Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data support further investigation of novel genetically...
Celularity Appoints Paul Graves as Chief Communications Officer
January 04, 2023 16:10 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies,...
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
November 10, 2022 17:00 ET
|
Celularity, Inc.
SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and Celularity Inc. (Nasdaq: CELU) (Celularity), a...
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022 16:10 ET
|
Celularity, Inc.
Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction (G/GEJ) cancerAppointed Adrian Kilcoyne, M.D.,...
Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
November 10, 2022 09:10 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and...
Celularity Promotes Two Executives in Executive Leadership Team
October 06, 2022 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placenta-derived allogeneic cell therapies,...
Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer
October 03, 2022 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...
Celularity to Present at Jefferies Cell and Genetic Medicine Summit
September 27, 2022 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...
Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro
September 26, 2022 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...
Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville
September 15, 2022 14:29 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...